P-008: Single center, real-world, retrospective assessment of outcomes with idecabtagene vicleucel (ide-cel) for relapsed/refractory myeloma after prior treatment with a BCMA-targeted therapy
Clinical Lymphoma Myeloma and Leukemia(2022)
Key words
relapsed/refractory myeloma,idecabtagene vicleucel,prior treatment,real-world,ide-cel,bcma-targeted
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined